Dr. Nghiem on Pembrolizumab for Advanced Merkel Cell Carcinoma

Video

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine discusses a phase II trial investigating the PD-1 blockade pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses a phase II trial investigating PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).

Adults with advanced, unresectable MCC, good performance status, and those who were not immune suppressed or did not have autoimmune disease were eligible for the trial. Pembrolizumab was administered at 2 mg/kg every 3 weeks. At the time of analysis, which was performed after 12-weeks of treatment, 24 patients had received pembrolizumab and 14 patients had been scanned for signs of disease, explains Nghiem.

Of the 14 evaluable patients, 10 responded to pembrolizumab; representing a 71% response rate, according to Nghiem. These responses consisted of 1 complete response (CR), 1 unconfirmed CR, 4 partial responses (PR), 2 unconfirmed PRs, and 2 progressions. While this data is still early, these results are very promising, especially in such a rare and difficult-to-treat disease, says Nghiem.

Although analysis of PD-L1 expression is still ongoing, Merkel polyomavirus-specific T cells, which are often found in patients with MCC, commonly express inhibitory coreceptors, such as PD-1. Additionally, MCC often expresses PD-L1, suggesting that this rare disease could be highly vulnerable to PD-1 inhibition.

<<<

View more from the 2015 European Cancer Congress

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.